Introduction: The frequency of extranodal involvement in lymphoma is not rare, but
variously described by authors in Africa. The objective of our work is to
describe the profile of patients followed for lymphoma with extranodal
locations. Methods: We conducted a descriptive, retrospective and
analytic study at the clinical hematology department of Dalal Jamm Hospital,
from September 2016 to June 2022. We included patients with a diagnosis of lymphoma
immunohistochemistry, with extranodal involvement. The epidemiological,
diagnostic, prognostic and survival aspects were studied. Results: Fifty-two (52) patients with extranodal localizations of their lymphoma were
included. The mean age was 44.2 ± 17.6 years and the sex ratio was 1.2. The average time to
diagnostic was 9.4 ± 3.6 months. We found a performance status ≥ 2 in 65.4% and
at least one B symptom in 71.2% of cases. The extranodal manifestations were digestive
(19%), cutaneous (17.5%), pleuropulmonary (17.5%), bone marrow (4.8%), thyroid
(1.6%), parotid gland (1.6%) and breast (1.6%). Patients presented with Hodgkin’s
lymphoma (HL) in 19.2% of cases and non-Hodgkin’s lymphoma (NHL) in 80.8% of
cases. At the end of the extension checkup reviews, 61.5% were at an advanced
stage and prognostic indices were unfavorable in 32% of patients. Conventional chemotherapy was conducted in
63.5% of patients of which
24 had NHL and 9 had HL. Immuno-chemoterapy was used in 26.9% of patients (13
cases of NHL, 1 case of HL). During the follow-up, we noted only 29.7% of
complete remission. The median overall survival was 25.1 months [23.5-34.1 months] in HL group and 20.5 months [18.7-72.2 months] in NHL patients (p
References
[1]
Thomas, A.-G., Vaidhyanath, R., Kirke, R. and Rajesh, A. (2011) Extranodal Lymphoma from Head to Toe: Part 1, the Head and Spine. AJR. American Journal of Roentgenology, 197, 350-356. https://doi.org/10.2214/AJR.10.7266
[2]
Zucca, E. and Cavalli, F. (2000) Extranodal Lymphomas. Annals of Oncology, 11, 219-222. https://doi.org/10.1093/annonc/11.suppl_3.219
[3]
Mezger, N.C.S., Feuchtner, J., Griesel, M., Hammerl, L., Seraphin, T.-P., Zietsman, A., et al. (2020) Clinical Presentation and Diagnosis of Adult Patients with Non-Hodgkin Lymphoma in Sub-Saharan Africa. British Journal of Haematology, 190, 209-221. https://doi.org/10.1111/bjh.16575
[4]
Mwamba, P.-M., Mwanda, W.-O., Busakhala, N.-W., Strother, R.-M., Patrick, J., Loehrer, P.-J. and Remick, S.-C. (2012) AIDS-Related Non-Hodgkin’s Lymphoma in Sub-Saharan Africa: Current Status and Realities of Therapeutic Approach. Lymphoma, 2012, Article ID: 904367. https://doi.org/10.1155/2012/904367
[5]
Zucca, E., Conconi, A. and Cavalli, F. (2002) Treatment of Extranodal Lymphomas. Best Practice and Research. Clinical Haematology, 15, 533-547. https://doi.org/10.1053/beha.2002.0218
[6]
Castillo, J.-J., Winer, E.-S. and Olszewski, A.-J. (2014) Sites of Extranodal Involvement Are Prognostic in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era: An Analysis of the Surveillance, Epidemiology and End Results Database. American Journal of Hematology, 89, 310-314. https://doi.org/10.1002/ajh.23638
[7]
AlShemmari, S.-H., Ameen, R.-M. and Sajnani, K.-P. (2008) Extranodal Lymphoma: A Comparative Study. Hematology, 13, 163-169. https://doi.org/10.1179/102453308X316149
[8]
Swerdlow, S.H., Campo, E., Pileri, S.A., et al. (2016) The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood, 127, 2375-2390. https://doi.org/10.1182/blood-2016-01-643569
[9]
Dupas, B., Augeul-Meunier, K., Frampas, E., Bodet-Milinc, C., Gastinne, T. and Le Gouill, S. (2013) Staging and Monitoring in the Treatment of Lymphomas. Diagnostic and Interventional Imaging, 94, 145-157. https://doi.org/10.1016/j.diii.2012.12.009
[10]
Musshoff, K. and Schmidt-Vollmer, H. (1975) Prognosis of Non-Hodgkin’s Lymphomas with Special Emphasis on the Staging Classification. Zeitschrift fur Krebsforschung und klinische Onkologie, 83, 323-341. https://doi.org/10.1007/BF00573019
[11]
Cuenca, X., Xhaard, A. and Mounier, N. (2009) Facteurs pronostiques dans les lymphomes non hodgkiniens et les lymphomes de Hodgkin. Bulletin du Cancer, 96, 461-473. https://doi.org/10.1684/bdc.2009.0844
[12]
Fournier, L., Ammari, S., Thiam, R. and Cuénod, C.-A. (2014) Imaging Criteria for Assessing Tumour Response: RECIST, mRECIST, Cheson. Diagnostic and Intervention Imaging, 95, 689-703. https://doi.org/10.1016/j.diii.2014.05.002
[13]
Reginelli, A., Urraro, F., Sangiovanni, A., Russo,G.-M., Russo, C., Grassi, R., Agostini, A., Belfiore, M.-P., Cellina, M., Floridi, C., Giovagnoni, A., Sica, A. and Cappabianca, S. (2020) Extranodal Lymphomas: A Pictorial Review for CT and MRI Classification. Acta Biomedica, 91, 34-42.
[14]
Niang, E.-H.-D., Faye, B.-F., Fall, S., Seck, M., Touré, A.-S., Sarr, K., Ndiaye, F.S.D. and Diop, S. (2022) Diagnosis and Follow-Up of Non-Hodgkin Lymphoma in Dakar, Senegal. Acta Scientific Cancer Biology, 6, 14-18.
[15]
Jaziri, H., Dahmeni, W., Ksiaa, M., Hammami, A., Ben Mansour, I., Brahem, A., Ajmi, S., Ben Samia, A. and Jmaa, A. (2016) Caractéristiques épidémio-cliniques, endoscopiques et histologiques des lymphomes primitifs du tube digestif (LPTD): Données d’une série tunisienne. La Revue de Médecine Interne, 37, A186-A187. https://doi.org/10.1016/j.revmed.2016.10.228
[16]
Ruskoné-Fourmestraux, A., Fabiani, B., Flejou, J.-F., Malamut, G. and Thieblemont, C. (2018) Lymphomes gastro-intestinaux. EMC-Gastroenterologie, 13(2): 1-15.
[17]
Guermazi, A., Brice, P., de Kerviler, E.-E., Fermé, C., Hennequin, C., Meignin, V. and Frija, J. (2001) Extranodal Hodgkin Disease: Spectrum of Disease. Radiographics, 21, 161-179. https://doi.org/10.1148/radiographics.21.1.g01ja02161
[18]
de La Motte Rouge, T. and Schneider, M. (2005) Anémie et lymphome. Bulletin du Cancer, 92, 429-431.
[19]
Fall, S., Ndiaye, F.S.D., Niang, E.H.D., Sarr, K., Séne, A., Camara, M.-L. and Niang, D. (2021) Profile of Adult Lymphomas in Sub-Saharan Africa: A Monocentric Study of Histoimmunochemical Aspects. Journal of Hematology and Blood Disorders, 7, 104.
